AstraZeneca PLC has agreed to pay Japan’s Daiichi Sankyo Co. up to $6.9 billion for part of the rights to a promising next-generation cancer treatment, as the Anglo-Swedish pharmaceutical group continues to strengthen its oncology drug pipeline.
The agreement for Daiichi Sankyo’s antibody drug conjugate trastuzumab deruxtecan includes a $1.35 billion upfront payment, with additional amounts based on regulatory and sales milestones, and other contingencies.
I have to say even by the standards of the onco space, this looks like a pricey deal. It sure puts to bed any idea that CNese lo-balling me-too onco mols are going to break the existing pricing model in developed markets any time soon!!
Dear ....Please share with ADULTS that 'Smoking,Alcoholism,Drug,PORN,Premarital Sex and Extramarital affairs' are very bad habits and explain the CONSEQUENCES with Logical points......This will also help for your CANCER prevention.